What is TiumBio Co., Ltd.'s (321550.KQ) StockRank?

MoatMap's StockRank for TiumBio Co., Ltd. (321550.KQ) is 7/100, with a Strong Sell signal. This is a composite score combining Quality (24), Value (38), and Momentum (26) factor ranks across MoatMap's 20,000+ stock universe.

Does TiumBio Co., Ltd. have an economic moat?

TiumBio Co., Ltd. (321550.KQ) has a Quality factor score of 24/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is TiumBio Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for TiumBio Co., Ltd. (321550.KQ) is Strong Sell, based on a StockRank of 7/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is TiumBio Co., Ltd. in?

TiumBio Co., Ltd. (321550.KQ) operates in the Healthcare sector, specifically the Biotechnology industry (South Korea).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

321550.KQ

STRONG SELLREMOVE

TiumBio Co., Ltd. · Healthcare · South Korea · $127M · Avg Vol: $1M/d

StockRank

P/E (TTM)

—

ROE

-31.8%

D/E

0.7x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

A clinical-stage biotech focused on rare diseases with binary clinical outcomes and high cash burn, failing our quality compounding criteria.

COMPANY DESCRIPTION

TiumBio Co., Ltd. is a clinical-stage biotechnology company dedicated to developing novel therapeutics for rare and intractable diseases, with a focus on oncology, immunology, and endocrinology. The company's competitive moat lies in its proprietary drug discovery platforms and a leadership team with a proven track record of successful global out-licensing deals. It operates as an R&D-intensive biotech player targeting high-value, underserved medical markets with significant commercial potential.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	6M	3M	4M	8M	10.5%
EPS	-0.82	-0.48	-0.53	-0.42	—
Shares	24M	25M	27M	27M	+13.0%
Debt	15M	19M	20M	21M	11.5%
Equity	40M	46M	35M	27M	-12.6%
Op CF	-11M	-14M	-10M	-10M	—
Inv CF	16M	-6M	16M	3M	—
Fin CF	2M	15M	-2M	3M	—

PRICE (1M)-63.1%

SMA 50SMA 200

$2.74

RSI (14)

12.4

52W High

$9.02

From 52W High

0.3%

SCORE BREAKDOWN

Quality

ROIC

-25.4%25.4

ROE

-31.8%24.3

GP/Assets

4.9%18.3

Op. Margin

-153.8%15.1

FCF/Assets

-7.0%32.4

Piotroski

—28.7

Int. Cover

-2.4x34.1

D/E Ratio

0.66x25.4

Current Ratio

1.39x21.7

Value

P/E (TTM)

—N/A

EV/EBITDA

-12.6x83.7

P/FCF

—N/A

P/B

3.4x35.3

P/S

9.9x26.2

Div Yield

—N/A

Momentum

52W High %

30%5.7

RS 6M

-154%2.6

SMA 50/200

1.22x90.6

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$127M

P/E (Forward)

—

Gross Margin

37.9%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 321550.KQ are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
321550.KQ	TiumBio Co., Ltd.(you)	$127M	7	STRONG SELL
095700.KQ	Genexine, Inc.	$111M	7	STRONG SELL
308430.KQ	Cellbion	$150M	8	STRONG SELL
394800.KQ	3billion	$154M	6	STRONG SELL
338840.KQ	Y-Biologics	$136M	3	STRONG SELL
308080.KQ	ViGenCell Inc.	$135M	12	STRONG SELL
138610.KQ	NIBEC Co., Ltd.	$141M	14	STRONG SELL
235980.KQ	MedPacto, Inc.	$80M	6	STRONG SELL
115450.KQ	HLB Therapeutics Co.,Ltd.	$147M	15	STRONG SELL
314130.KQ	Genome & Company	$146M	16	STRONG SELL

Peer medians: ROE -1.1% · P/E 17.7x · Gross margin 43.6%

TiumBio Co., Ltd. (321550.KQ) — Stock Score Summary

TiumBio Co., Ltd. (321550.KQ) has a MoatMap StockRank of 7/100 based on Quality (24/100), Value (38/100), and Momentum (26/100) factor scores. The current signal is STRONG SELL. A clinical-stage biotech focused on rare diseases with binary clinical outcomes and high cash burn, failing our quality compounding criteria.

Key Financial Metrics

Price	$2.74
Market Cap	$127M
Price/Book	3.41
Return on Equity	-31.8%
Return on Invested Capital	-25.4%
Debt/Equity	65.61
Gross Margin	37.9%
Operating Margin	-153.8%
Revenue Growth	40.1%
Free Cash Flow	$-3K

TiumBio Co., Ltd. operates in the Biotechnology industry, part of the Healthcare sector (South Korea).

Frequently Asked Questions

What is TiumBio Co., Ltd.’s (321550.KQ) StockRank?: MoatMap’s StockRank for TiumBio Co., Ltd. (321550.KQ) is 7/100, with a Strong Sell signal. It is a composite of Quality (24), Value (38), and Momentum (26) factor ranks across MoatMap’s 20,000+ stock universe.
Does TiumBio Co., Ltd. have an economic moat?: TiumBio Co., Ltd. (321550.KQ) has a Quality factor score of 24/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is TiumBio Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for TiumBio Co., Ltd. (321550.KQ) is Strong Sell, based on a StockRank of 7/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is TiumBio Co., Ltd. in?: TiumBio Co., Ltd. (321550.KQ) operates in the Healthcare sector, specifically the Biotechnology industry (South Korea).